Tetrahedron Letters 56 (2015) 834-836

Contents lists available at ScienceDirect

Tetrahedron Letters

journal homepage: www.elsevier.com/locate/tetlet

A stereoselective approach for the total synthesis of (-)-tadanalactam from acetonide-p-glucose



etrahedro

Saidulu Konda, Bhaskar Kurva, Lingaiah Nagarapu*, Akkewar M. Dattatray[†]

Organic Chemistry Division-II (CPC), Indian Institute of Chemical Technology (CSIR), Tarnaka, Hyderabad 500007, India

ARTICLE INFO

ABSTRACT

Article history: Received 12 November 2014 Revised 17 December 2014 Accepted 21 December 2014 Available online 29 December 2014

Keywords: Birch reduction Pinnick oxidation Staudinger reaction 2-Piperidone Tadanalactam

alactam, has been accomplished from the commercially existing acetonide-D-glucose involving Birch reduction, Pinnick oxidation, Staudinger reaction, and hydroboration reactions. Finally benzyl ether deprotection and subsequent oxirane formation using Birch reduction completed the total synthesis of (-)-tadanalactam. © 2015 Elsevier Ltd. All rights reserved.

A stereoselective and realistic approach for the total synthesis of naturally occurring δ -lactam (–)-tadan-

Substituted 2-piperidones (δ -lactam), exhibiting interesting biological activities, are present in numerous natural products such as alkaloids and drugs. Therefore, efficient stereoselective syntheses of functionalized 2-piperidone derivatives are of importance in medicinal chemistry. 2-Piperidone moiety (Fig. 1) is found in $3\beta_4\alpha$ -dihydroxy-2-piperidinone (**3**) and 5,6-dihydro-2(1*H*)-pyridinone (**4**) isolated¹ from *Piper longum*, showing a superior anti-HBV activity in vitro, Piperlongumine (PL) alkaloid (5) with anti-cancer activity, isolated² from the various parts of long pepper, *Piper lon*gum L. also possesses 2-piperidone in its structure. (3S,4R)-3,4dihydroxy-1-(3-phenylpropanoyl)piperidin-2-one (6) isolated³ from Piper longum, demonstrated significant activity, with IC₅₀ values of 1.80 and 0.21 mM against HBsAg (hepatitis B virus surface antigen) and HBeAg (hepatitis B virus e antigen) correspondingly. Kaousine (7) isolated⁴ from the aerial part of *Piper capense* L.f (Piperaceae), shows lower antiplasmodial activity. Alkaloids, Piplaroxide (8), isolated⁵ from *Piper tuberculatum*, 3,4-epoxy-8,9dihydropiplartine (**9**) isolated⁶ from leaves and twigs of *Piper verrucosum*, and 3,4-epoxy-5-pipermethystine (10) isolated⁷ from roots of the kava shrub (Piper methysticum) are all substituted piperidones.

(–)-Tadanalactam, $(3\alpha, 4\alpha$ -epoxy-2-piperidone), an antifungal agent, was first isolated from sponge Tedania ignis and its chemical and biological characterization was carried out in 1994 by

E-mail addresses: lnagarapuiict@yahoo.com (L. Nagarapu), dattatray.akkewar@ gmail.com (A.M. Dattatray).

[†] Tel.: +91 40 27191511; fax: +91 40 27193382.

Cardellina et al.⁸ In 2007, Lago et al.⁹ reported the isolation and characterization of (-)-tadanalactam from the leaves of Piper crass*inervium* (piperaceae). In 2009 Tilve and co-workers¹⁰ reported the total synthesis and stereochemistry of (-)-tadanalactam (1) and (+)-tadanalactam (2) by following a synthetic route with tandem Oxidation-Wittig reaction and Sharpless asymmetric dihydroxylation as the key steps. In continuation of our research program focused toward the total synthesis of bioactive molecules from inexpensive and readily accessible starting materials,¹¹ we have established an effective approach utilizing Birch reduction, Pinnick oxidation, Staudinger reaction, hydroboration, and reductive elimination reactions, for the linear stereoselective synthesis of (-)tadanalactam (1), starting from the abundantly available acetonide-p-glucose.

As shown retrosynthetically (Scheme 1), synthesis of (-)-tadanalactam could be accomplished from **18**, via Birch reduction, which in turn could be prepared from 17 by reduction (Staudinger reaction), followed by cyclization. Compound 17 is accessible from 15 via acetonide deprotection, oxidative cleavage, and Pinnick oxidation followed by esterification. Hydroboration of 13 resulted in the primary alcohol, which was then converted into azido compound 15, by tosylation, followed by nucleophilic substitution reaction. Compound 13 could be achieved from 11 by O-benzylation, regioselective acetonide deprotection, oxidative cleavage, and finally reduction.

Our synthesis (Scheme 2) started with acetonide-D-glucose (11), which was converted to O-benzylated compound by a known protocol.^{12,13} Regioselective deprotection of the 5,6 acetonide group in O-benzylated compound with 0.8% H₂SO₄ in MeOH for 5 h afforded



^{*} Corresponding author. Tel.: +91 40 27191509; fax: +91 40 27193382.



Figure 1. Naturally and synthetically occurring 2-piperidones.

the dihydroxy compound 12 with 95% yield. Reductive elimination¹⁴ of **12** with iodine–PPh₃–imidazole in toluene at reflux conditions for 2 h gave olefin 9 in 86% yield. Compound 9 was subjected to hydroboration¹⁵ using 9-BBN, which resulted in the addition of borane, regioselectively at C-3 position in 4 h, which was immediately subjected to oxidation with H₂O₂ in the presence of 3 N NaOH at rt to provide the primary alcohol 14 in 93% yield. The primary alcohol was converted into the corresponding tosylate with p-toluenesulfonyl chloride and catalytic amount of DMAP in pyridine/ CH₂Cl₂ to furnish O-tosylated compound, which was then treated with sodium azide in DMF at 60 °C for 12 h to give 15 in 87% yield. Deprotection of 1,2-acetonide in 15 with 4% H₂SO₄ in THF at reflux temperature for 12 h afforded diol 16 in 94% yield. Oxidative cleavage of the diol 16, with NaIO₄ in methanol/water furnished the aldehyde, which was then subjected to oxidation (Pinnick oxidation) using NaClO₂ and H₂O₂ in methanol/water for 4 h in the presence of a basic buffer NaH₂PO₄ to afford the acid, which was then



Scheme 1. Retrosynthetic analysis of (-)-tadanalactam.



 $\begin{array}{l} \textbf{Scheme 2.} Reagents and conditions: (a) (i) Ref. 12 (ii) 0.8\% H_2SO_4, MeOH, rt, 8 h, 95\%; (b) PPh_3, imidazole, l_2, toluene, reflux, 4 h, 86\%; (c) (i) 9-BBN, THF, 0 °C, rt, 4 h. (ii) 3 N NaOH, H_2O_2, rt, 3 h, 93\% (for two steps); (d) (i) Ts-Cl, Et_3N, DCM, 0 °C, rt, 2 h. (ii) NaN_3, DMF, 60 °C, 5 h, 87\% (for two steps); (e) 4\% H_2SO_4, THF, reflux, 6 h, 94\%; (f) (i) NaIO_4, MeOH/H_2O (2:1), rt, 0.5 h. (ii) NaClO_2, NaH_2PO_4, H_2O_2, MeOH/H_2O, 0 °C, rt, 4 h. (iii) SOCl_2, MeOH, 0 °C, rt, 12 h (overall 3 steps), 76\%; (g) (i) Ts-Cl, Py, DCM, 0 °C, rt, 8 h, (ii) PPh_3, THF:H_2O (8:2), rt, 3 h, (overall 2 steps), 92\%; (h) Li/liq. NH_3, -78 °C, 10 min, 78\%. \end{array}$

(without further purification) taken up for selective methylation (esterification) in the presence of SOCl₂ in methanol for 12 h at room temperature to furnish the ester **17**. Reaction of **17** with *p*-toluenesulfonyl chloride in pyridine and catalytic amount of DMAP produced the tosylate, at this stage, reduction of azide using the Staudinger conditions. That is, treatment with triphenylphosphine in THF/H₂O resulted in one-pot reductive lactonization, to give lactam **18** in 76% yield. Compound **18** was subsequently subjected to deprotection of the benzylether using Li/liq.NH₃ in dry THF (Birch reduction). The ammonia present in the reaction facilitated the oxirane ring formation, thus forming the target molecule (–)-tadanalactam in a single step with 78% yield. The spectroscopic data¹⁶ were in agreement with the recently synthesized structure of (–)-tadanalactam (**1**).¹⁰

In conclusion, a stereoselective synthesis of (–)-tadanalactam has been achieved from the commercially available acetonide-D-glucose via a high yielding route (34% overall yield) by using Birch reduction, Pinnick oxidation, Staudinger reaction, hydroboration, and reductive elimination reactions.

Acknowledgments

The authors gratefully acknowledge DST-SERB/EMEQ-078/2013 for financial assist. S. Konda and B.K. thank CSIR – India for award of research fellowship.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.tetlet.2014.12. 115.

References and notes

- 1. Zhi-Yong, J.; Wen-Feng, L.; Xue-Mei, Z.; Jie, L.; Yun-Bao, M.; Ji-Jun, C. Bioorg. Med. Chem. Lett. 2013, 23, 2123-2127.
- Kumar, S.; Kamboj, J.; Suman, S. S. J. Acupunct. Meridian. Stud. 2011, 4, 134.
- Zhi-Yong, J.; Wen-Feng, L.; Chao-Guan, H.; Xiang-Zhong, H. Fitoterapia 2013, 84, 3 222-226
- 4. Mohamed, A. K.; Valerie, M. L.; Cecile, C.; Laurent, D. S. H.; Nadine, A. E. O. Fitoterapia **2010**, 81, 632–635.
- Capron, M. A.; Weimer, D. F. J. Nat. Prod. 1996, 59, 794. 5
- Seeram, N. P.; Lewis, P. A.; Jacobs, H. J. Nat. Prod. 1996, 59, 436. 6.
- Dragull, K. Y., Yoshida, W. Y.; Tang, C. Phytochemistry **2003**, 64, 555. Cronan, J. M. J.; Cardellina, J. H., Il *Nat. Prod. Lett.* **1994**, *5*, 85. Lago, J. H.; Kato, M. J. *Nat. Prod. Res.* **2007**, *21*, 910. 7
- 8.
- 9
- Mahesh, S. M.; Perunninakulath, S. P.; Santosh, G. T. J. Org. Chem. 2009, 74, 10. 6378-6381.
- (a) Saidulu, K.; Bhaskar, K.; Nagarapu, L.; Dattatray, M. A. *Tetrahedron Lett.* **2014**, *55*, 3087–3089; (b) Nagarapu, L.; Paparaju, P.; Satyander, A.; Bantu, R. 11 *Tetrahedron Lett.* **2011**, 52, 7075–7078: (c) Bantu, R.: Merevala, H. B.: Nagarapu, L.; Kantevari, S. Tetrahedron Lett. **2011**, 52, 4854–4856; (d) Nagarapu, L.; Mallepalli, R.; Yeramanchi, L.; Bantu, R. Tetrahedron Lett. 2011, 52, 3401-3404; (e) Nagrapu, L; Mallepalli, R; Nikil Kumar, U; Paparaju, P; Bantu, R; Yeramanchi, L. *Tetrahedron Lett.* **2012**, *53*, 1699–1700; (f) Nagarapu, L; Gaikward, H. K.; Bantu, R.; Manikonda, S. R. Eur. J. Med. Chem. 2011, 46, 2152–2156; (g) Nagarapu, L.; Karnakanti, S.; Bantu, R. Tetrahedron 2012, 68, 5829-5832
- Xiaochao, X.; Zhaojun, Y.; Xiangbao, M.; Zhongjun, L. J. Org. Chem. 2013, 78, 12 9354-9365.
- 13
- Makoto, K.; Fumiaki, N. *Carbohydr. Res.* **2002**, 337, 951–954. Gangavaram, V. M. S.; Sudhakar, K.; Ravi, R.; Kongari, N.; Pendem, N.; Chirutha, C.; Kiran, S. K.; Ajit, C. K. *Chem. Asian J.* **2009**, *4*, 181–193. 14.
- 15. Ching-Yun, H.; I-Chi, L.; Larry, S. L.; Biing-Jiun, U.; Shang-Cheng, H. J. Chin. Chem. Soc. 2012, 59, 421-425.

16. Spectral data for selected compounds:

(3aR,5R,6S,6aR)-5-(2-azidoethyl)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3d][1,3]dioxole (**15**): IR(KBr) ν cm⁻¹: 2926, 2097, 1454, 1075. ¹H NMR (300 MHz, CDCl₃) δ: 7.38–

7.30 (m, 5H, Ar-H), 5.91 (d, J = 3.81 Hz, 1H), 4.71 (d, J = 11.90 Hz, 1H), 4.63 (d, J = 3.96 Hz, 1H), 4.48 (d, *J* = 1.1.90 Hz, 1H), 4.23 (m, 1H), 3.81 (d, *J* = 3.20 Hz, 1H), 3.36 (ddd, *J* = 1.98, 5.95, 7.62 Hz, 2H), 2.03–2.10 (m, 1H), 1.90–1.81 (m, 1H), 1.49 (s, 3H), 1.32 (s, 3H). ¹³C NMR (CDCl₃) δ: 137.3, 128.5, 128.0, 127.7, 111.5, 104.6, 82.2, 82.0, 71.7, 48.5, 27.8, 26.6, 26.1. MS (ESI) m/z: 342 [M+Na]⁺ (2S,3R)-methyl5-azido-2-(benzyloxy)-3-hydroxy pentanoate (17).

IR(KBr) v cm⁻¹: 3445, 2926, 2100, 1747, 1455, 1266, 1129, 750. ¹H NMR (300 MHz, CDCl₃) δ: 7.39–7.31 (m, 5H, Ar-H), 4.81 (d, J = 11.44 Hz, 1H), 4.45 (d, J = 11.44 Hz, 1H), 4.00 (br s, 1H), 3.88 (d, J = 4.12 Hz, 1H), 3.79 (s, 3H, OCH₃), 3.41 (dd, J = 5.95, 7.47 Hz, 2H), 1.82 (ddd, J = 1.83, 3.96,5.79, 9.76, 1H), 1.73– 1.66 (m, 1H). ¹³C NMR (CDCl₃) δ : 171.0, 136.5, 128.5, 128.3, 128.2, 80.2, 72.9, 69.6, 52.1, 47.9, 32.4. MS (ESI) m/z: 302 [M+Na]⁺.

(-)-Tadanalactam (1): To a freshly distilled ammonia (3 mL) taken in a 50 mL two-necked round-bottomed flask fitted with a coldfinger condenser were added freshly cut lithium metal pieces (0.015 g, 21.3 mmol) at -78 °C and the resulting gray suspension was stirred for 30 min, then the compound 18 (0.2 g, 5.3 mmol) in anhydrous THF (20 mL) was added and stirred at -78 °C for 10 min. The reaction mixture was quenched with solid NH₄Cl portion wise and then ammonia was allowed to evaporate. Then mixture was diluted with water (10 mL) and extracted with EtOAc (3 \times 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (60-120mesh, MeOH/EtOAc = 0.2:9.8) to afford compound 1 (0.046 g, 78%) as a yellow oil. $[\alpha]_D^{27} = -7.21$ (*c* 0.162 MeOH) [lit.¹⁰. $[\alpha]_D^{27} - 7.6$ (*c* 0.130, MeOH)]. IR(KBr) ν cm⁻¹: 3303, 2925, 1684, 1119, 622. ¹H NMR (500 MHz, CDCl₃): δ 5.68 (s, 1H, NH), 3.64 (br s, 1H), 3.42 (dd, J = 4.1, 2.4, 1H), 3.36 (dd, J = 12.3, 6.1, 1.4 Hz, 1H), 3.05 (dd, J = 12.3, 6.1, 1.4 Hz, 1H), 2.38– 2.26 (m, 1H), 2.07 (dd, J = 12.3, 6.1, 1.4 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃): δ 169.6, 53.0, 50.8, 34.3, 23.5. HRMS (ESI) m/z calcd. for C₅H₈O₂N [M+H]⁺. 114.0550, found 114.0549.